metaLinear
Alderley Edge
About metaLinear
metaLinear focuses on the identification and validation of new drug targets for difficult to treat bacterial infections. metaLinear uses a proprietary proteome engineering platform technology to uncover, characterise and validate new targets for antibiotics. Using very large libraries of Randomised proteins (R-teins) expressed in target bacteria, metaLinear will screen for novel targets responsible for the desired phenotype. A key advantage of this approach is the ability to de-risk targets and hence provide multiple efficiency gains in the traditional target and drug discovery process.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $339.3K
- Funding stage: Seed
- Last round: Seed (Nov 2017)
- Website: metalinear.co.uk
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/metalinear-170202 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.